11/29/2012 9:43:57 AM
NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. (OTCBB: RBCC) nears a new joint venture agreement to commercialize advances made by Amarantus BioSciences (OTCBB: AMBS), the company’s latest target continues to seek out additional investment capital from high-profile investors. Amarantus Chief Science Officer John W. Commissiong recently presented his organization’s brilliant MANF therapeutic protein for Parkinson’s disease at the Scientific Session of CNS Summit 2012 in Boca Raton. The CNS Summit brings together researchers, developers and investors to collaborate in bringing new treatments to patients suffering from brain disorders.
comments powered by